How do TB-500 and GHK-Cu differ?
TB-500 is a 17-amino-acid thymosin β4 fragment acting via G-actin sequestration and integrin-linked kinase signalling; GHK-Cu is a copper-tripeptide acting via copper-dependent fibroblast and keratinocyte signalling. Different size, different mechanism, different research-application emphasis. Both appear in the Glow Blend and KLOW Blend combined formulations.
What the research literature says
The compounds differ structurally (17-aa acetylated peptide vs 3-aa copper-complexed tripeptide) and mechanistically (actin-binding + integrin-linked kinase vs copper-dependent fibroblast and keratinocyte signalling). TB-500’s published research base spans cardiac repair (PMID 15565145, PMID 22236126), dermal healing (PMID 27450738), and limb-ischemia angiogenesis (PMID 32945357). GHK-Cu’s published research base spans dermal wound-healing (PMID 19319546), skin-regeneration pathway modulation (PMID 26236730), and oxidative-stress contexts (PMID 22666519).
Application emphasis differs accordingly. TB-500’s research base concentrates on cardiac, limb-ischemia, and dermal-healing contexts; GHK-Cu’s research base concentrates on dermal, skin-regeneration, and hair-follicle contexts. Both compounds appear in the Glow Blend (with BPC-157 as the third component) and KLOW Blend (adding KPV) where the non-overlapping mechanism arms support combined-research protocols.
Researchers selecting between the compounds for a specific research context should anchor the choice to the experimental application — cardiac and limb-ischemia research points toward TB-500; skin-regeneration and dermal-research points toward GHK-Cu; combined-mechanism research uses the blend formats.
Why this matters in research context
The comparison matters in peptide-research contexts as a common selection question for skin-and-tissue-repair research protocols. The substantive answer is that the compounds are mechanistically complementary rather than substitutable — most published research uses either one or the other depending on application context, with combined-research protocols leveraging the non-overlapping mechanism arms via the blend formats.
Related compounds
- TB-500 10mg — cytoskeletal-remodeling pharmacology
- GHK-Cu 50mg — copper-dependent fibroblast pharmacology
- Glow Blend — combined-formulation including both
Related research questions
References
- Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432(7016):466-472. [PMID 15565145]
- Kang YA et al. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch Dermatol Res 2009;301(4):301-306. [PMID 19319546]
- Pickart L et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015;2015:648108. [PMID 26236730]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.